PROJECT SUMMARY The proposed conference, entitled “Endometrial Cancer: New Biology Driving Research and Treatment,” will be held November 7-9, 2020 in Miami, Florida. This will be the first AACR conference focused specifically on advances in endometrial cancer (EC). Over the last decade, the incidence of EC has been increasing globally. If current trends continue, in the United States the incidence of EC will double by 2030. Furthermore, the number of women dying from EC has also been increasing disproportionately to the rise in incidence, with rates exceeding those seen for most other solid tumors. There are few therapeutic options for women diagnosed with recurrent or metastatic EC, and median overall survival (OS) is short. No new agents have been approved for the treatment of EC in the past two decades. Emerging molecular knowledge of EC has led to clinical trials testing actionable events in molecularly defined recurrent EC patient populations. Molecular subtypes of EC have been well defined by The Cancer Genome Atlas Program and are now being incorporated into clinical trials and transitioned into clinical practice. Tangentially, based on these studies, the FDA has approved therapies based on microsatellite instability and mutational burden. Many emerging therapies are based on molecular characterization of EC in addition to histologic subtypes. There are also many cooperative group clinical trials completed, in progress, and approved for EC using novel biologic approaches. This suggests that numerous opportunities exist for diagnostics, prognostics, and therapeutics that would benefit from an AACR special conference. To this end, the AACR is seeking support to expand the conference and to recruit outstanding young investigators through additional travel awards. Attendance by this “next generation” of cancer scientists and caregivers will help better disseminate the rapidly growing collection of research innovations as well as ignite powerful collaborations. The program has been carefully designed to feature thought-provoking sessions on molecular stratification, DNA repair and replication, functional genomics and proteomics, novel model systems, immunotherapy, and targeted therapies. Collaboration and networking will be encouraged by incorporating multiple opportunities for education, thoughtful discussion, and meaningful interaction between participants.